
Opinion|Videos|July 8, 2024
AE Management With IO-TKI and IO-IO in RCC
Author(s)Martin H. Voss, MD
Martin H. Voss, MD, outlines adverse events encountered with different IO-TKI and IO-IO combination regimens in RCC and discusses the importance of open communication with patients.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What are the most significant adverse events seen with different IO-TKI and IO-IO combination regimens used in renal cell carcinoma (RCC)?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5



























